eligibility_summary
Key eligibility: Adults 18-75 with CD30+ Hodgkins lymphoma or anaplastic large cell lymphoma, ECOG 0-1 (dose escalation) or 0-2 (expansion), >=1 evaluable lesion (Lugano 2014), expected survival >=3 months, adequate labs, contraception, consent. Exclude: insufficient washout from prior therapy, prior CAR-T or allo-HSCT, severe disease, HBV/HCV/HIV positive, any condition deemed unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1, single-arm, open-label study in China testing LCAR-HL30, an autologous CD30-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory Hodgkin’s lymphoma and anaplastic large cell lymphoma. Mechanism: patient T cells are genetically modified to express a CAR that binds CD30 (TNFRSF8) on malignant lymphocytes, triggering MHC-independent T-cell activation and cytotoxic killing, with in vivo expansion/persistence. Pre-infusion lymphodepletion uses cyclophosphamide (alkylating DNA crosslinker) and fludarabine (purine analog) to enhance CAR-T engraftment. Targets: CD30+ Reed-Sternberg/ALCL cells and the CD30 pathway.